Twist Bioscience Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Haemonetics (HAE) and Twist Bioscience (TWST) shares reached over 5-year highs. HAE rose 2% due to a renewed deal with CSL Plasma, with Citi upgrading it to 'Buy' and raising its target to $123. TWST surged 11% following its AI drug discovery partnership with Eli Lilly's TuneLab, with Leerink raising its target to $160.
Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
Twist Bioscience (TWST) shares rose 3% after announcing a partnership with Eli Lilly's Lilly TuneLab. The deal involves providing antibody characterization data services for TuneLab's AI/ML drug discovery platform. According to Twist's CEO, the partnership aims to accelerate antibody drug discovery by combining experimental data with AI models.
Over the past 7 days, AlphAI's AI scored 12 news stories mentioning TWST (Twist Bioscience Corp). Coverage has skewed bullish: 11 bullish, 1 neutral, and 0 bearish.
Recent TWST coverage spans market movers, technology and insider activity.
In the last 30 days, TWST insiders filed 24 SEC Form 4 transactions — no purchases and 24 sales ($20.2M). The most active reporter was Finn Patrick John, President and COO, with 8 filings. 54% of those filings were made under pre-arranged Rule 10b5-1 plans.
Collaboration expands Twist’s AI exposure and could accelerate revenue growth toward a $1B target by 2031.
Collaboration could boost pipeline and revenue.
The partnership could boost Twist's revenue and market visibility in antibody services.
Collaboration may increase Twist's service revenue and visibility in AI‑driven biotech.
The article frames the TuneLab collaboration as a growth catalyst while simultaneously highlighting stretched valuation and ongoing unprofitability.
AlphAI scores every news story that mentions TWST with an AI model for sentiment and relevance, and aggregates insider trades from Twist Bioscience Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Haemonetics (HAE) and Twist Bioscience (TWST) shares reached over 5-year highs. HAE rose 2% due to a renewed deal with CSL Plasma, with Citi upgrading it to 'Buy' and raising its target to $123. TWST surged 11% following its AI drug discovery partnership with Eli Lilly's TuneLab, with Leerink raising its target to $160.
2 min readVicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min readTwist Bioscience (TWST) shares rose 3% after announcing a partnership with Eli Lilly's Lilly TuneLab. The deal involves providing antibody characterization data services for TuneLab's AI/ML drug discovery platform. According to Twist's CEO, the partnership aims to accelerate antibody drug discovery by combining experimental data with AI models.
2 min readEli Lilly's AI/ML drug discovery platform, Lilly TuneLab, partners with Twist Bioscience to provide antibody characterization data. Twist's services will support TuneLab's antibody developability prediction model, AbLab, aiming to accelerate drug discovery. Twist's CEO highlights the importance of high-quality data for AI models. The partnership leverages Twist's scale and TuneLab's AI capabilities, offering preferred protocols and pricing for users.
2 min readTwist Bioscience (TWST) and Ginkgo Bioworks partnered with Eli Lilly's TuneLab for AI-driven drug discovery. TWST's P/S ratio is 20.65x, above its historical median, with a GF Score™ of 69. Insiders sold $73.6M shares, while gurus show mixed interest. The company is unprofitable, with a GF Value™ suggesting overvaluation.
7 min readARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
2 min readGreen Paula (SVP of Human Resources) sold 907 shares of Twist Bioscience Corp (TWST) at $122.62 ($0.11M total) on 2026-09-08.
1 min readLeproust Emily M. (Chief Executive Officer) sold 2,302 shares of Twist Bioscience Corp (TWST) at $122.62 ($0.28M total) on 2026-09-08.
1 min readCathie Wood's Ark Invest sold shares of Palantir (PLTR) and AMD (AMD), and bought shares of Robinhood (HOOD) and Cerebras (CBRS). The trades were valued at $6.5M, $9.9M, $3.2M, and $6.5M respectively. Palantir and AMD saw recent partnerships and strong earnings, while Robinhood and Cerebras have seen market volatility.
2 min readTwist Bioscience (TWST) officer Paula Green filed a Rule 144 notice to sell up to 907 shares, valued at $111K, following prior sales totaling 26,137 shares. The shares are tied to restricted stock vesting and include tax obligations. Sales were executed through Fidelity Brokerage Services on NASDAQ.
1 min read
